Gaucher Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Gaucher Disease Clinical Trials Report Overview
The Gaucher disease clinical trials report provides an overview of the clinical trials, including top-line data. The data highlights the number of trial numbers and their average enrolment in top countries conducted across the globe. Furthermore, the clinical trials for Gaucher disease are elaborated by region, country (G7 & E7), phase, trial status, end points status, and sponsor type, in this report.
Key Regions | · Asia-Pacific
· Europe · North America · Middle East and Africa · South and Central America |
Key Countries | · The US
· Israel · The UK · Spain · Canada · Japan · Russia · Argentina · Italy · India |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Sanofi
· Takeda Pharmaceutical Co Ltd · Pfizer Inc · Protalix BioTherapeutics Inc · ISU Chemical Co Ltd · Eli Lilly and Co · Others |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Gaucher Disease Clinical Trials Segmentation by Regions and Countries
North America led the Gaucher disease clinical trials landscape with more than 25% of the clinical trials conducted there as of September 2023.
The key regions considered for Gaucher disease clinical trials analysis are Asia-Pacific, Europe, North America, Middle East and Africa, and South and Central America. As of September 2023, North America led the Gaucher disease clinical trials landscape.
In a country-wise analysis, as of September 2023, the US accounted for the highest number of Gaucher disease clinical trials, followed by Israel and the UK.
G7 countries: Among the G7 (United States, United Kingdom, Germany, Canada, Japan, France, and Italy) countries, the UK has the highest proportion of Gaucher disease to Metabolic Disorders clinical trials as of September 2023.
E7 countries: Among the E7 (China, India, Russia, Turkey, Brazil, Mexico, and Indonesia) countries, Russia has the highest proportion of Gaucher disease to Metabolic Disorders clinical trials as of September 2023.
Gaucher Disease Clinical Trials Analysis by Regions, 2023 (%)
Buy Full Report for More Regional Insights into the Gaucher Disease Clinical Trials
Gaucher Disease Clinical Trials Segmentation by Sponsor Types
The key sponsor types for Gaucher Disease clinical trials are company, institution, and the government. As of September 2023, the company sponsor type dominated the Gaucher disease clinical trials share, followed by institution.
Gaucher Disease Clinical Trials Analysis by Sponsor Type, 2023 (%)
Buy Full Report for More Sponsor Type Insights into Gaucher Disease Clinical Trials
Gaucher Disease Clinical Trials - Competitive Landscape
In 2023, Sanofi conducted the highest number of Gaucher disease clinical trials.
A few of the leading sponsors for Gaucher disease clinical trials are:
- Sanofi
- Takeda Pharmaceutical Co Ltd
- Pfizer Inc
- Protalix BioTherapeutics Inc
- ISU Chemical Co Ltd
- Eli Lilly and Co
Sanofi accounted for the highest market share of Gaucher disease clinical trials in 2023.
Gaucher Disease Clinical Trials Analysis by Sponsors, 2023 (%)
Buy Full Report to Know More About the Leading Players of Gaucher Disease Clinical Trials Download a Free Sample Report
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies concerning investment.
- Helps identify prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps identify key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Takeda Pharmaceutical Co Ltd
Pfizer Inc
Protalix BioTherapeutics Inc
ISU Chemical Co Ltd
Eli Lilly and Co
Amicus Therapeutics Inc
Belrose Pharma Inc
AVROBIO Inc
eResearchTechnology Inc (Inactive)
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of Gaucher disease clinical trials?
North America accounted for the highest number of Gaucher disease clinical trials as of September 2023.
-
Which country conducted the highest number of Gaucher disease clinical trials?
The US conducted the highest number of Gaucher disease clinical trials as of September 2023.
-
Which sponsor type was the most prominent in the Gaucher disease clinical trials?
Company was the most prominent sponsor type for Gaucher disease clinical trials.
-
Who are the leading sponsors of Gaucher disease clinical trials?
Some of the leading sponsors of Gaucher disease clinical trials are Sanofi, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Protalix BioTherapeutics Inc, ISU Chemical Co Ltd, and Eli Lilly and Co, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.